[Ip-health] Bloomberg: Rush to Buy Merck’s Covid Pill Risks Leaving Poor Countries Behind
thiru at keionline.org
Tue Oct 12 01:18:43 PDT 2021
Rush to Buy Merck’s Covid Pill Risks Leaving Poor Countries Behind
By James Paton + Follow
October 12, 2021, 6:00 AM GMT+2
WHO-backed effort faces pressure to avert shot inequity replay
Drugmaker, health groups seek to extend treatment’s reach
Moves by a small group of countries to acquire supplies of Merck & Co.’s
promising Covid pill before it’s even approved are raising concerns that
some poorer nations could be left behind in a repeat of the slow and
inequitable rollout of vaccines.
A global initiative to deploy Covid therapies like Merck’s molnupiravir is
at risk of running into the same problems the Covax effort faced and has no
clear mechanism to negotiate contracts and supply countries, according to
an independent report commissioned by the World Health Organization.
Merck has taken a series of steps, including licensing its experimental
medication to generic-drug firms, to ensure access. Yet, in a worrisome
echo of the global vaccine situation, some wealthy and middle-income
nations, including Australia, Singapore, Malaysia and Thailand, have
followed the U.S. and already secured molnupiravir or started talks to
Merck’s experimental antiviral, molnupiravir.
The therapies arm of the ACT-Accelerator, which is working to distribute
Covid treatments around the world, has expanded access to the steroid
dexamethasone, analyzed more than 1,700 clinical trials to identify new
treatments and funded large trials. Still, nations that have struggled to
vaccinate their populations could end up in the back of the line for brand
new therapies like Merck’s pill.
The program “does not yet have a clearly articulated procurement structure
to supply countries or to negotiate contracts,” according to the report
from consulting firm Dalberg Advisors that was based on interviews with
more than 100 government, company and health-group officials, among others.
The WHO-backed effort “could face similar challenges to Covax in ensuring
sufficient supply” for poor and middle-income countries, the review found,
highlighting the advanced purchase of molnupiravir by the U.S. as a risk.
Efforts are underway to avert the scenario seen with vaccines and widen
access to the treatment, a potential boon to poorer countries because of
its low production cost and ease of use. Merck signed licensing agreements
with Indian generic manufacturers aimed at supplying more than 100 lower-
and middle-income countries, should the therapy get approved, while global
health group Unitaid and its partners are in supply discussions.
“The concerns I think are understandable, but we’ve put in place a strategy
with our voluntary license partners that will be able to meet the demand
and really bring this medicine to patients worldwide who need it,” said
Paul Schaper, executive director of global pharmaceutical public policy at
Officials are anxious not to replay the disappointments of Covax, the
program coordinated by the WHO and other groups to distribute vaccines. The
effort has been hobbled by a lack of supplies after rich nations rushed
ahead to protect their own populations, with some already beginning to give
“Have we learned our lesson?” said Rachel Cohen, North America regional
executive director for the nonprofit Drugs for Neglected Diseases
Initiative. “The majority of people in low- and middle-income countries
haven’t been vaccinated and could potentially benefit tremendously from
this treatment if they got it early enough.”
The emergence of novel antivirals like molnupiravir is good news, but
testing needs to be ramped up to detect cases in the first days of
infection when the drugs may be most effective, Cohen said. How much they
will cost -- and who will receive them and who won’t if supplies are
limited -- remain key questions.
Countries are already lining up behind the U.S., which agreed in June to
pay Merck about $1.2 billion for 1.7 million treatment courses, or about
$700 per course. Australia, Malaysia, Singapore and New Zealand have
already secured supplies, while Thailand was finalizing its own pact last
week. In all, about 10 countries have either signed deals or are in talks
to do so, according to London-based Airfinity Ltd.
Hopes are running high that the drug will be widely available. In April,
Merck licensed it to Indian companies including Cipla Ltd., Dr. Reddy’s
Laboratories Ltd. and Hetero Labs Ltd. The company also has been in
discussions with the Medicines Patent Pool to weigh additional licenses and
said it plans to implement a tiered pricing approach based on World Bank
Merck itself said it expects to produce 10 million courses by the end of
the year as it seeks emergency use authorization in the U.S. “Substantially
more” should become available next year, Schaper said.
The ACT-Accelerator was launched last year by the WHO and other
organizations to spur the development and equitable delivery of Covid
vaccines, tests and therapies. The coalition has played an important role,
but has grappled with external and internal challenges that have hampered
its progress, according to the report published Friday. The WHO said in a
statement that recommendations will be incorporated into a revised strategy.
Unitaid, one of the groups overseeing the therapies campaign, is working to
ensure new treatments are ready as soon as the WHO or others approve them,
but more than $3 billion is needed to fund the effort next year, a
representative, Herve Verhoosel, wrote in a statement.
“With therapeutics, the pipeline is more complex and there are more
entities involved than with vaccines, which makes procuring new treatments
more complicated,” according to Unitaid.
Covid therapies could be critical for many countries due to the risk of
further variants and low immunization levels. More than 55 countries had
yet to vaccinate 10% of their populations as of last week.
“The countries where we don’t have widespread access to vaccines are the
exact same countries where treatment will be more urgently needed,” said
Suerie Moon, co-director of the Global Health Centre at the Graduate
Institute of International and Development Studies in Geneva.
If new treatments like Merck’s become available soon, “rapid preemptive
action” will be needed to make sure the delivery effort doesn’t face
similar challenges to Covax, the report said.
— With assistance by Riley Griffin
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org
More information about the Ip-health